Financial_NNP Statements_NNP 97_CD 8_CD INTANGIBLE_NNP ASSETS_NNP Product_NNP marketing_NN and_CC Software_NNP distribution_NN Other_JJ development_NN Goodwill_NNP rights_NNS intangibles_VBZ costs_NNS Total_JJ $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD Cost_NN At_IN 1_CD January_NNP 2003_CD 1,254_CD 2,537_CD 398_CD 352_CD 4,541_CD Additions_NNS -_: separately_RB acquired_VBN 1_CD 38_CD 32_CD 61_CD 132_CD Additions_NNS -_: internally_RB developed_VBN 43_CD 43_CD Exchange_NNP and_CC other_JJ movements_NNS 52_CD 382_CD 5_CD 6_CD 445_CD At_IN 31_CD December_NNP 2003_CD 1,307_CD 2,957_CD 435_CD 462_CD 5,161_CD Additions_NNS separately_RB acquired_VBD 42_CD 40_CD 74_CD 156_CD Additions_NNS internally_RB developed_VBD 59_CD 59_CD Exchange_NNP and_CC other_JJ movements_NNS 18_CD 203_CD 2_CD 1_CD 224_CD At_IN 31_CD December_NNP 2004_CD 1,325_CD 3,202_CD 477_CD 596_CD 5,600_CD Additions_NNS separately_RB acquired_VBD 43_CD 57_CD 76_CD 176_CD Additions_NNS internally_RB developed_VBD Exchange_NNP and_CC other_JJ movements_NNS 45_CD 442_CD 31_CD 23_CD 541_CD At_IN 31_CD December_NNP 2005_CD 1,280_CD 2,803_CD 503_CD 649_CD 5,235_CD Amortisation_NNP and_CC impairment_NN losses_NNS At_IN 1_CD January_NNP 2003 310 827 275_CD 242_CD 1,654_CD Amortisation_NNP for_IN the_DT year_NN 204_CD 28_CD 64_CD 296_CD Impairment_NN charge_NN 7_CD 7_CD Exchange_NNP and_CC other_JJ movements_NNS 14_CD 155_CD 8_CD 177_CD At_IN 31_CD December_NNP 2003_CD 324_CD 1,186_CD 318_CD 306_CD 2,134_CD Amortisation_NNP for_IN year_NN 220_CD 25_CD 61_CD 306_CD Impairment_NN charge_NN 10_CD 10_CD Exchange_NNP and_CC other_JJ movements_NNS 2_CD 101_CD 8_CD 5_CD 100_CD At_IN 31_CD December_NNP 2004_CD 336_CD 1,507_CD 335_CD 372_CD 2,550_CD Amortisation_NNP for_IN year_NN 214_CD 19_CD 39_CD 272_CD Exchange_NNP and_CC other_JJ movements_NNS 9_CD 288_CD 3_CD 5_CD 299_CD At_IN 31_CD December_NNP 2005_CD 327_CD 1,433_CD 357_CD 406_CD 2,523_CD Net_JJ book_NN value_NN At_IN 31_CD December_NNP 2003_CD 983_CD 1,771_CD 117_CD 156_CD 3,027_CD At_IN 31_CD December_NNP 2004_CD 989_CD 1,695_CD 142_CD 224_CD 3,050_CD At_IN 31_CD December_NNP 2005_CD 953_CD 1,370_CD 146_CD 243_CD 2,712_CD Amortisation_NNP and_CC impairment_NN charges_NNS Amortisation_NNP and_CC impairment_NN charges_NNS are_VBP recognized_VBN in_IN selling_NN ,_, general_JJ and_CC administrative_JJ expenses_NNS in_IN the_DT income_NN statement_NN ._.
The_DT impairment_NN in_IN 2004_CD was_VBD in_IN relation_NN to_TO the_DT write-off_NN of_IN goodwill_NN associated_VBN with_IN Exanta_NNP ._.
The_DT impairment_NN in_IN 2003_CD was_VBD in_IN respect_NN of_IN amounts_NNS capitalized_VBN in_IN relation_NN to_TO collaboration_NN arrangements_NNS with_IN NicOx_NNP and_CC in_IN respect_NN of_IN ANG453_NNP ,_, which_WDT were_VBD terminated_VBN ._.
For_IN the_DT purposes_NNS of_IN impairment_NN testing_NN of_IN goodwill_NN ,_, the_DT Group_NNP is_VBZ regarded_VBN as_IN a_DT single_JJ ,_, cash-generating_JJ unit_NN ._.
The_DT cash-generating_JJ units_NNS recoverable_JJ amount_NN is_VBZ based_VBN on_IN value_NN in_IN use_NN using_VBG projections_NNS of_IN the_DT Groups_NNS performance_NN over_IN ten_CD years_NNS ,_, a_DT period_NN reflecting_VBG the_DT patent-protected_JJ lives_NNS of_IN our_PRP$ current_JJ products_NNS ._.
A_DT risk-adjusted_JJ discount_NN rate_NN of_IN 12_CD %_NN has_VBZ been_VBN applied_VBN to_TO the_DT projections_NNS ._.
Material_NNP assets_NNS Carrying_VBG Remaining_VBG value_NN amortisation_NN Description_NN $_$ m_JJ period_NN Goodwill_NNP in_IN the_DT US_NNP Goodwill_NNP 707_CD Not_RB amortised_JJ Intangible_JJ assets_NNS arising_VBG from_IN joint_JJ venture_NN with_IN Merck_NNP Product_NNP ,_, marketing_NN and_CC distribution_NN rights_NNS 368_CD 8_CD and_CC 12_CD years_NNS Advance_NNP payment_NN Product_NNP ,_, marketing_NN and_CC distribution_NN rights_NNS 668_CD 13_CD years_NNS These_DT assets_NNS are_VBP associated_VBN with_IN the_DT restructuring_NN of_IN the_DT joint_JJ venture_NN with_IN Merck_NNP &_CC Co._NNP ._.
Inc._NNP ._.
